RISING TIDES
Observations from the IMC Research Process

Data is the New Medicine

Diagnostics are entering a technology-driven acceleration that will reshape healthcare economics.

• The Clinical Data Flywheel. After a decade of advances, better chemistry, faster sequencing, and AI-driven bioinformatics are finally pushing high-sensitivity diagnostics like MRD (Minimal Residual Disease) and MCED (Multi-Cancer Early Detection) into everyday clinical workflows. The sector is shifting from static “tests that confirm disease” to active tools that guide care, promising superior patient outcomes and massive system-wide cost savings.
• The Inflection Point. Three forces are creating this new paradigm:
  • Technological Sensitivity: Faster, cheaper sequencing and better error-correction techniques deliver the accuracy needed to detect disease signals earlier.
  • Payor Alignment: Health systems and insurers prioritize early detection to shift costs and eliminate expensive, unnecessary late-stage treatment.
  • Data Moat: Proprietary datasets of biological markers and genomic profiles create a compounding flywheel where more samples lead to superior, AI-powered algorithms.
• Strategics Are Paying Up. The recent ABT’s $23 billion acquisition of EXAS is the clearest signal – large strategics are willing to pay a premium for platforms that deliver high-recurrence surveillance, early detection, and clear clinical impact. This transaction validates the recurring revenue model driving the entire sector. Companies like NTRA and GH – along with multi-omics platforms such as ADPT and CSTL, and next-generation methylation leaders like GRAL – are positioned to benefit from the same tailwinds.

The future of healthcare will be defined by who owns the data that powers the next generation of precise, predictive, and profitable diagnostics.